Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration

Marinomed Biotech AG / Key word(s): Insolvency

Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration

16-Jul-2026 / 23:10 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by - a service of .

The issuer is solely responsible for the content of this announcement.

Korneuburg, Austria, 16th July 2026 – Marinomed Biotech AG (VSE:MARI) announces the plan to apply for the initiation of a court restructuring proceeding without self-administration. The application is being filed because the court-approved restructuring plan dated November 14, 2024, cannot be fulfilled due to the breakdown of negotiations by Unither and the failure of Unither Pharmaceuticals to make earn-out payments from the sale of the Carragelose business unit, thereby placing the company at risk of insolvency. The aim of the renewed restructuring proceedings without self-administration is to secure the company's financial stability by concluding a new restructuring plan. In addition to further restructuring measures, the legal options available against Unither arising from the sale of the Carragelose business and the assets of the Marinosolv platform are to be utilized. +++ End of ad-hoc announcement +++ End of Inside Information

16-Jul-2026 CET/CEST News transmitted by

2367244 16-Jul-2026 CET/CEST

Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.